期刊
COMMUNICATIONS BIOLOGY
卷 2, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s42003-019-0327-4
关键词
-
资金
- University of Wisconsin Carbone Cancer Center Support Grant [P30 CA014520]
- UW 20/20 grant
- NIH Director's Early Independence Award [DP5OD024576]
- NHLBI/NIH [T32 HL07899]
- Stand Up to Cancer St. Baldrick's Pediatric Dream Team Translational Research Grant [SU2C-AACR-DT1113]
- NCI/NIH [K08 CA174750]
- MACC Fund
Finding improved therapeutic strategies against T-cell Non-Hodgkin's Lymphoma (NHL) remains an unmet clinical need. We implemented a theranostic approach employing a tumortargeting alkylphosphocholine (NM600) radiolabeled with Y-86 for positron emission tomography (PET) imaging and Y-90 for targeted radionuclide therapy (TRT) of T-cell NHL. PET imaging and biodistribution performed in mouse models of T-cell NHL showed in vivo selective tumor uptake and retention of Y-86-NM600. An initial toxicity assessment examining complete blood counts, blood chemistry, and histopathology of major organs established Y-90-NM600 safety. Mice bearing T-cell NHL tumors treated with Y-90-NM600 experienced tumor growth inhibition, extended survival, and a high degree of cure with immune memory toward tumor reestablishment. Y-90-NM600 treatment was also effective against disseminated tumors, improving survival and cure rates. Finally, we observed a key role for the adaptive immune system in potentiating a durable anti-tumor response to TRT, especially in the presence of microscopic disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据